undamentalytics Newsletter
Sign in

Twist Bioscience Corp (TWST) stock

Add to watchlist

Add holding +

NASDAQ: TWST Nasdaq Life Sciences Tools & Services Next results ~November 12, 2026

C Fundamentals grade

Twist Bioscience Corp is a US-listed company in the life sciences tools & services industry. Its financial year ends in September.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Twist Bioscience Corp is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Twist Bioscience Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 10 selling0 purchases and 180 sales by directors and officers, last 12 monthsInsider trades
  • Funds185 adding, 132 cuttingOf 60 active managers that changed their stake, 38 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Twist Bioscience files

Where Twist Bioscience stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $432m, up 19.2% on a year earlier, faster than the 17.8% growth a quarter earlier. That growth ranks 5 of 31 among the life sciences tools & services companies we cover. Free-cash-flow margin fell to -21.6% from -19.0% a year earlier. Operating margin widened to -33.6% from -39.3%. The diluted share count is up 2.4% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks.

Our model value for Twist Bioscience is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 3, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Twist Bioscience Corp's trailing-twelve-month revenue grew 19.2% year on year, with a free-cash-flow margin of -21.6%.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 35.5% while net income fell 60.5%: a 25pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 19.2% over the last 12 months, against a median of 6.9% for life sciences tools & services companies we cover.
  • Margins widening. Operating margin is up 5.7 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Loss-making. Operating margin is -33.6%: costs exceed revenue.
  • Burning cash. Free cash flow was -21.6% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 15.4% of revenue, against a median of 4.4% for life sciences tools & services companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 2.4% in a year.
  • High sales multiple. The shares trade at 18 times revenue while operating margins remain thin.
  • Volatile shares. Over the past year the shares showed annualised volatility of 81% and a beta of 2.9 against the S&P 500.

Latest results: FY2026 Q3

Filed August 3, 2026
Earnings per share
-$0.56 against an average estimate of -$0.28: missed by 98.5%
Revenue
$118m, up 23.2% on a year earlier
Share reaction
+8.6% in the first session after the results on August 3, 2026, against +3.3% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.20

Twist Bioscience's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-15.5%
  • 1 week-11.2%
  • 1 month-31.6%
  • This year+306.8%
  • 1 year+292.3%
  • 5 years-4.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$432M
Operating margin
-33.6%
Net margin
-31.7%
EPS (TTM, diluted)
$-2.24

Growth

Revenue growth
+19.2%
Change in growth rate
+1.4 pts
Share count change
+2.4%

Cash

Free cash flow (TTM)
-$93.1M
FCF margin
-21.6%
Stock pay % of revenue
15.4%

Earnings

Last results
August 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Insider trade
  3. Insider trade
  4. Insider trade
  5. Insider trade
  6. Announcement
  7. Agreement
  8. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Twist Bioscience Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Twist Bioscience Corp as an operating company, with every model that fits that kind of business. Cost of equity 11.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.47 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$6.1 ~$3.5–$8.2 Left out: out of range vs price (0.05x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$26 ~$21–$54 Left out: out of range vs price (0.20x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$5.6 ~$4.0–$7.6 Left out: out of range vs price (0.04x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Twist Bioscience Corp with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2019202020212022202320242025Now
Share price$23.88$75.97$106.97$35.24$20.26$45.18$28.14$129.04
Market value$656m$3.0bn$5.2bn$1.9bn$1.2bn$2.6bn$1.7bn$7.9bn
+ Net debt (− = net cash)−$39m−$89m−$464m−$379m−$286m−$226m−$183m−$117m
Enterprise value$617m$2.9bn$4.7bn$1.5bn$866m$2.4bn$1.5bn$7.8bn
Multiples
Price / sales 12.1x33.0x39.0x9.3x4.7x8.4x4.5x18.3x
Price / earnings ————————
Price / free cash flow ————————
EV / EBITDA ————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

11 /100

Weak moat

How hard Twist Bioscience's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -12.5% of total assets over 7 years.

  • Pricing power 6 / 20

    Gross margin has been a median 40.2%, moving by 13.9 percentage points (standard deviation) across 8 years.

  • Durability 10 / 20

    Operating margin has been a median -101.5%; its worst year was -206.1%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 8 years, at a median -83.8% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 29.7% over five years; stock-based pay has been a median 18.0% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (16 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $124m and EPS of −$0.20 (range −$0.38 to −$0.02) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.20 +44% $456m +21%
Next −$0.40 +67% $549m +20%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.8% on 90 days ago. In the last 30 days, 2 analysts raised Twist Bioscience Corp's forecast and 0 cut it.

Consensus EPS forecast Twist Bioscience Corp, last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.19 Current fiscal year, 60 days ago: −$1.08 Current fiscal year, 30 days ago: −$0.96 Current fiscal year, 7 days ago: −$0.96 Current fiscal year, Now: −$1.20 −$1.20 Next fiscal year, 90 days ago: −$1.00 Next fiscal year, 60 days ago: −$0.78 Next fiscal year, 30 days ago: −$0.75 Next fiscal year, 7 days ago: −$0.75 Next fiscal year, Now: −$0.40 −$0.40

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.19−$1.00
60 days ago −$1.08−$0.78
30 days ago −$0.96−$0.75
7 days ago −$0.96−$0.75
Now −$1.20−$0.40

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.28 −$0.56 −98.5%
Mar 2026 −$0.53 −$0.60 −12.6%
Dec 2025 −$0.52 −$0.50 +3.9%
Sept 2025 −$0.50 −$0.45 +10.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

13 analysts, Oct 2026
Buy969%
Hold323%
Sell18%

Monthly trend

  1. Oct 2026273113
  2. Sep 2026273113
  3. Aug 202627211
  4. Jul 202627211

Counts of recommendations published by analysts covering Twist Bioscience Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
19.4%
of tradable shares
Days to cover
3.22
at average volume
Short interest, 1 month
−18%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.9%
of shares
Employees
979
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +292.3%

$32.89 on October 31, 2025 to $129.04

ThenNowEffect
Revenue (last 12 months) $362m $432m +19.2%
P/S multiple 5.4x 18.3x +237.2%
Share count 60m 61m −2.4%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +591.5%

$18.66 on November 3, 2023 to $129.04

ThenNowEffect
Revenue (last 12 months) $235m $432m +83.4%
P/S multiple 4.5x 18.3x +307.6%
Share count 57m 61m −7.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
TWST−45%−69%+55%+26%−32%+307%
Industry peers (median)+5%−51%−3%−15%−2%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
TWST33%25%50%50%42%73%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
TWST−64%−74%−63%−38%−55%−37%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 31, 2018: 95% from January 20, 2021 to May 2, 2023. Getting back needed a 1710% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$25.45 – $205.00
From 52-week high
−37.1%
vs 50-day average
−15.5%
vs 200-day average
+44.3%
Volatility (1 year)
81%
Beta vs S&P 500
2.86

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±12.8%
After a week
6 up, 6 down
typical move ±17.9%
After a month
8 up, 4 down
typical move ±23.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 3, 2026 +8.6% +3.3% +36.4% +44.2%
May 4, 2026 −6.1% +0.4% −6.9% +19.8%
February 2, 2026 +12.8% −0.4% +15.6% +17.0%
January 12, 2026 +13.9% 0.0% +17.9% +40.5%
November 14, 2025 −11.5% −0.9% −4.5% +4.1%
August 4, 2025 −18.3% +1.0% −18.0% −22.8%
May 5, 2025 −16.5% −1.4% −16.0% −22.4%
February 3, 2025 −0.7% 0.0% −7.1% −19.7%
November 18, 2024 +12.0% +0.8% +25.8% +20.9%
August 2, 2024 −14.6% −4.7% −17.1% −22.8%
May 2, 2024 +28.9% +2.2% +35.2% +37.7%
February 2, 2024 +9.5% +0.7% +14.8% +10.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Twist Bioscience Corp in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Twist Bioscience Corp
$200M $250M $300M $350M $400M $450M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $245.1M Revenue (TTM), FY24 Q1: $262.4M Revenue (TTM), FY24 Q2: $277.5M Revenue (TTM), FY24 Q3: $295.2M Revenue (TTM), FY24 Q4: $313M Revenue (TTM), FY25 Q1: $330.2M Revenue (TTM), FY25 Q2: $347.7M Revenue (TTM), FY25 Q3: $362.3M Revenue (TTM), FY25 Q4: $376.6M Revenue (TTM), FY26 Q1: $391.6M Revenue (TTM), FY26 Q2: $409.5M Revenue (TTM), FY26 Q3: $431.8M $431.8M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $245.1M
FY24 Q1 $262.4M
FY24 Q2 $277.5M
FY24 Q3 $295.2M
FY24 Q4 $313M
FY25 Q1 $330.2M
FY25 Q2 $347.7M
FY25 Q3 $362.3M
FY25 Q4 $376.6M
FY26 Q1 $391.6M
FY26 Q2 $409.5M
FY26 Q3 $431.8M
Revenue growth, TTM YoY Twist Bioscience Corp
15% 20% 25% 30% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 20.4% Revenue growth, TTM YoY, FY24 Q1: 21.6% Revenue growth, TTM YoY, FY24 Q2: 21.8% Revenue growth, TTM YoY, FY24 Q3: 25.4% Revenue growth, TTM YoY, FY24 Q4: 27.7% Revenue growth, TTM YoY, FY25 Q1: 25.9% Revenue growth, TTM YoY, FY25 Q2: 25.3% Revenue growth, TTM YoY, FY25 Q3: 22.7% Revenue growth, TTM YoY, FY25 Q4: 20.3% Revenue growth, TTM YoY, FY26 Q1: 18.6% Revenue growth, TTM YoY, FY26 Q2: 17.8% Revenue growth, TTM YoY, FY26 Q3: 19.2% 19.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 20.4%
FY24 Q1 21.6%
FY24 Q2 21.8%
FY24 Q3 25.4%
FY24 Q4 27.7%
FY25 Q1 25.9%
FY25 Q2 25.3%
FY25 Q3 22.7%
FY25 Q4 20.3%
FY26 Q1 18.6%
FY26 Q2 17.8%
FY26 Q3 19.2%
Operating margin (TTM) Twist Bioscience Corp
-100% -50% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -88.6% Operating margin (TTM), FY24 Q1: -83.7% Operating margin (TTM), FY24 Q2: -74.5% Operating margin (TTM), FY24 Q3: -79.6% Operating margin (TTM), FY24 Q4: -70.6% Operating margin (TTM), FY25 Q1: -63.1% Operating margin (TTM), FY25 Q2: -57.9% Operating margin (TTM), FY25 Q3: -39.3% Operating margin (TTM), FY25 Q4: -36.2% Operating margin (TTM), FY26 Q1: -34.4% Operating margin (TTM), FY26 Q2: -33.9% Operating margin (TTM), FY26 Q3: -33.6% -33.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -88.6%
FY24 Q1 -83.7%
FY24 Q2 -74.5%
FY24 Q3 -79.6%
FY24 Q4 -70.6%
FY25 Q1 -63.1%
FY25 Q2 -57.9%
FY25 Q3 -39.3%
FY25 Q4 -36.2%
FY26 Q1 -34.4%
FY26 Q2 -33.9%
FY26 Q3 -33.6%
FCF margin (TTM) Twist Bioscience Corp
-80% -60% -40% -20% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -69.5% FCF margin (TTM), FY24 Q1: -49.1% FCF margin (TTM), FY24 Q2: -34.4% FCF margin (TTM), FY24 Q3: -25.4% FCF margin (TTM), FY24 Q4: -22.1% FCF margin (TTM), FY25 Q1: -20.7% FCF margin (TTM), FY25 Q2: -18.8% FCF margin (TTM), FY25 Q3: -19.0% FCF margin (TTM), FY25 Q4: -20.1% FCF margin (TTM), FY26 Q1: -22.1% FCF margin (TTM), FY26 Q2: -23.2% FCF margin (TTM), FY26 Q3: -21.6% -21.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -69.5%
FY24 Q1 -49.1%
FY24 Q2 -34.4%
FY24 Q3 -25.4%
FY24 Q4 -22.1%
FY25 Q1 -20.7%
FY25 Q2 -18.8%
FY25 Q3 -19.0%
FY25 Q4 -20.1%
FY26 Q1 -22.1%
FY26 Q2 -23.2%
FY26 Q3 -21.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2017 Sept 2017 2018 Sept 2018 2019 Sept 2019 2020 Sept 2020 2021 Sept 2021 2022 Sept 2022 2023 Sept 2023 2024 Sept 2024 2025 Sept 2025 LTM Jun 2026
Income
Revenue 11 25 54 90 132 204 245 313 377 432
Gross profit −13 −7 7 29 52 84 90 133 191 224
EBITDA −53 −65 −103 −133 −143 −218 −188 −189 −111 −120
Operating income −58 −71 −109 −140 −153 −235 −217 −221 −136 −145
Net income −59 −71 −108 −140 −152 −218 −205 −209 −78 −137
Diluted EPS −$24.49 −$25.51 −$3.92 −$3.57 −$3.15 −$4.04 −$3.60 −$3.60 −$1.30 −$2.24
Growth (year on year)
Revenue — +136.2% +113.9% +65.7% +46.9% +53.8% +20.4% +27.7% +20.3% +19.2%
Margins
Gross margin −123.1% −26.6% 12.8% 31.8% 39.1% 41.4% 36.6% 42.6% 50.7% 52.0%
EBITDA margin −496.5% −255.0% −188.9% −148.1% −108.0% −107.2% −76.6% −60.5% −29.6% −27.8%
Operating margin −543.2% −277.5% −200.1% −155.5% −115.4% −115.3% −88.6% −70.6% −36.2% −33.6%
Net margin −550.8% −280.2% −198.0% −155.3% −114.9% −107.0% −83.5% −66.7% −20.6% −31.7%
Free-cash-flow margin −537.7% −274.7% −188.8% −168.8% −105.3% −111.1% −69.5% −22.1% −20.1% −21.6%
Cash flow
Cash from operations −51 −66 −88 −142 −112 −124 −142 −64 −48 −53
Capital spending 7 4 15 10 27 102 28 5 28 40
Free cash flow −58 −70 −103 −152 −139 −226 −170 −69 −76 −93
Stock-based pay 2 3 11 17 37 80 30 51 64 66
Free cash flow after stock pay −60 −73 −114 −169 −176 −306 −201 −120 −140 −160
Balance sheet
Cash 31 81 47 94 466 379 286 226 183 117
Total debt 0 10 8 5 2 — 0 0 0 0
Net debt (negative = net cash) −31 −71 −39 −89 −464 −379 −286 −226 −183 −117
Diluted shares 2,422m — 27m 39m 48m 54m 57m 58m 60m 61m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $672m
Short-term assets $321mLonger-term assets $351m
What it owes, and who funded it · $672m
Short-term liabilities $120mLonger-term liabilities $106mShareholders' equity $446m
  • Short-term assets cover short-term liabilities $321m of assets due within a year against $120m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $321m short-term assets against $106m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Twist Bioscience Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+2.4%
year over year
R&D spending
16.6%
of revenue
Sales & admin spending
67.2%
of revenue
Days sales outstanding
55 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated TWST CSTL VCYT FLGT AZTA TXG Median
Revenue, last 12 months $432m $357m $562m $324m $614m $617m $229m
Revenue growth, last 12 months 19.2% 3.2% 17.3% 6.8% 4.9% −4.3% 6.9%
Revenue growth, 3-year average 22.4% 28.7% 19.6% 1.8% −0.9% 2.8% 2.9%
Revenue growth, latest quarter 23.2% 20.1% 15.5% 4.4% 12.0% −12.6% 8.5%
Gross margin 52.0% 77.3% 71.7% 35.6% 44.0% 70.0% 51.9%
Operating margin −33.6% −9.0% 18.8% −37.7% −28.6% −14.3% −14.3%
Operating margin, 3-year average −50.8% −7.0% 1.6% −42.5% −15.0% −23.3% −22.4%
Net margin −31.7% −5.4% 20.4% −26.0% −20.0% −12.2% −16.1%
Cash from operations / revenue −12.3% 11.9% 31.7% −25.8% 6.2% 20.6% 1.3%
Free-cash-flow margin −21.6% −0.1% 29.5% −32.0% 1.6% 19.7% −2.2%
Free-cash-flow margin, 3-year average −22.0% 5.6% 19.0% −15.9% 5.0% 7.8% 0.6%
Stock pay / revenue 15.4% 12.6% 8.6% 11.6% 3.1% 16.0% 4.4%
Change in share count 2.4% −0.7% 2.5% −1.5% −1.1% 4.2% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 19.2% 6.9% 12 of 54
Change in growth rate Growth +1.4pp +0.4pp 19 of 54
Gross margin Profitability 52.0% 52.0% 23 of 45
Operating margin Profitability -33.6% -14.3% 32 of 52
Net margin Profitability -31.7% -12.2% 35 of 54
Free-cash-flow margin Cash generation -21.6% -1.3% 39 of 54
Stock pay as % of revenue Cash generation 15.4% 4.4% 42 of 53
Change in share count Balance sheet 2.4% 1.0% 29 of 46
Days sales outstanding Balance sheet 55 days 62 days 19 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to September 30, 2025
Products and services
Line of business Revenue Share YoY
Ngs Tools $208M 55.3% ▲ 23.0%
Synthetic Genes $114M 30.2% ▲ 22.6%
Antibody Discovery $23.5M 6.2% ▲ 15.4%
Oligo Pools $20.2M 5.4% ▲ 19.7%
Dna and Biopharma Libraries $11.2M 3.0% ▼ 19.7%
Geography
Region Revenue Share YoY
Americas $226M 59.9% ▲ 16.3%
EMEA $124M 33.0% ▲ 34.2%
Asia Pacific $26.8M 7.1% ▲ 0.9%

From Twist Bioscience Corp's 10-K filed November 17, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$7.9B
Institutions reporting
335
Shares held vs prior quarter
▼ 0.9%
Positions opened / closed
86 / 31

Top buyers and sellers, Q2 2026: 185 institutions bought and 132 sold ; the biggest buyer was Price T Rowe Associates Inc (+3.6M shares) and the biggest seller William Blair Investment Management, LLC (−3.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $600M 5.8M 7.6% ▲ 5.0%
Artisan Partners Limited Partnership $494M 4.8M 6.3% ▼ 24.6%
FMR LLC $484M 4.7M 6.2% ▲ 148.8%
ARK Investment Management LLC $468M 4.5M 6.0% ▼ 28.3%
Price T Rowe Associates Inc $374M 3.6M 4.8% ▲ 5069.8%
State Street Corp $333M 3.2M 4.2% ▼ 11.9%
Vanguard Portfolio Management LLC $291M 2.8M 3.7% ▲ 6.6%
Vanguard Capital Management LLC $278M 2.7M 3.5% ▲ 2.3%
Edgepoint Investment Group Inc. $259M 2.5M 3.3% ▼ 53.2%
William Blair Investment Management, LLC $224M 2.2M 2.8% ▼ 58.7%
Farallon Capital Management, L.L.C. $220M 2.1M 2.8% ▲ 49.6%
Invesco Ltd. $198M 1.9M 2.5% ▼ 11.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Twist Bioscience Corp's complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $147M 180 trades by 10 insiders · 82% under pre-set plans
Net ▼ $147M net selling
Insider Date Trade Shares Price Value
Finn Patrick John President and COO October 23, 2026 Sell 2,245 $134.59 $302,152
Laponis Adam Chief Financial Officer October 9, 2026 Sell 2,462 $156.30 $384,823
Leproust Emily M. Chief Executive Officer October 5, 2026 Sell pre-set plan 45 $207.46 $9,336
Leproust Emily M. Chief Executive Officer October 5, 2026 Sell pre-set plan 146 $206.84 $30,199
Leproust Emily M. Chief Executive Officer October 5, 2026 Sell pre-set plan 297 $205.78 $61,116
Leproust Emily M. Chief Executive Officer October 5, 2026 Sell pre-set plan 290 $204.80 $59,392
Leproust Emily M. Chief Executive Officer October 5, 2026 Sell pre-set plan 432 $203.61 $87,958
Leproust Emily M. Chief Executive Officer October 5, 2026 Sell pre-set plan 1,017 $202.32 $205,763
Leproust Emily M. Chief Executive Officer October 5, 2026 Sell pre-set plan 481 $201.26 $96,804
Leproust Emily M. Chief Executive Officer October 5, 2026 Sell pre-set plan 1,840 $200.44 $368,806
Werner Robert F. Chief Accounting Officer October 2, 2026 Sell 1,482 $188.88 $279,926
Cho Dennis See Remarks October 2, 2026 Sell 9,514 $188.88 $1.8M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 2 trades and filings

No trades in Twist Bioscience Corp disclosed in the last 12 months; 2 earlier trades on record.

  • Dwight Evans(D-PA 3):Sale (full), $1,001 - $15,000, traded March 30, 2022, filed April 25, 2022
  • Dwight Evans(D-PA 3):Purchase, $1,001 - $15,000, traded March 2, 2020, filed April 23, 2020

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 2, 2026 estimated from the company's past filing pattern, not announced

  • August 3, 2026
  • May 4, 2026
  • February 2, 2026
  • January 12, 2026
  • November 14, 2025
  • August 4, 2025

Recent SEC filings

Data status

When each part of this page on Twist Bioscience Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Twist Bioscience Corp in brief

What does Twist Bioscience Corp do?
Twist Bioscience Corp is a US-listed company in the life sciences tools & services industry. Its financial year ends in September.
What is Twist Bioscience Corp's stock ticker?
Twist Bioscience Corp trades under the ticker TWST on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Twist Bioscience Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Twist Bioscience Corp reported revenue of $432M, 19.2% higher than a year earlier, according to its SEC filings.
What is Twist Bioscience Corp's free cash flow?
Twist Bioscience Corp's free-cash-flow margin is -21.6% of revenue over the trailing twelve months, ranking 39 of the 54 life sciences tools & services companies we cover.
Who are Twist Bioscience Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Artisan Partners Limited Partnership and FMR LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Twist Bioscience Corp's market cap?
On November 2, 2026, Twist Bioscience Corp's market capitalisation was about $7.9B and net debt of -$117M. Market figures come from third-party market data and may be delayed.
Who are Twist Bioscience Corp's competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Twist Bioscience Corp are Castle Biosciences Inc, Veracyte, Inc., Fulgent Genetics, Inc., Azenta, Inc. and 10x Genomics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Twist Bioscience Corp's.
Are insiders buying or selling Twist Bioscience Corp stock?
Over the last 12 months, Twist Bioscience Corp's directors and officers reported 0 open-market purchases and 180 sales on Form 4. The insider trading page charts every trade.
When is Twist Bioscience Corp's next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Twist Bioscience Corp announces its own schedule.